News
Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not ...
GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...
Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...
Clinical trials show weight loss between 15% to 21% for GLP-1s, but this study suggests that weight loss in the real world is ...
Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...
Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body ...
In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...
(Reuters) -Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss that can ...
14h
GlobalData on MSNNovo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomesNovo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...
Scholar Rock's latest trial returned very positive results. Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, ...
Scholar Rock said its investigational therapy helped preserve lean mass among patients taking a powerful weight loss drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results